iLIVER最新文献

{"title":"Optimising postoperative surveillance for hepatocellular carcinoma: Beyond histological predictors","authors":"Jiahao Xu , Lihui Gu , Tian Yang","doi":"10.1016/j.iliver.2024.100110","DOIUrl":"10.1016/j.iliver.2024.100110","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100110"},"PeriodicalIF":0.0,"publicationDate":"2024-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000355/pdfft?md5=08e6e95a553cdb667d6ca485e4835264&pid=1-s2.0-S2772947824000355-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142048341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic research on MASLD: New insights into cardiovascular disease and cancer risk","authors":"Ming Yang, Juan Liu","doi":"10.1016/j.iliver.2024.100108","DOIUrl":"10.1016/j.iliver.2024.100108","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100108"},"PeriodicalIF":0.0,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000331/pdfft?md5=45e308ef2f4897a9eff0d22fcfb13eeb&pid=1-s2.0-S2772947824000331-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142048342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor burden score and alpha-fetoprotein level predict prognosis of patients with unresectable hepatocellular carcinoma treated with tyrosine kinase inhibitor and anti-PD-1 antibody","authors":"Shichuan Tang ,&nbsp;Tingfeng Huang ,&nbsp;Cong Luo ,&nbsp;Jun Fu ,&nbsp;Kailing Zhang ,&nbsp;Qingjing Chen ,&nbsp;Jie Kong ,&nbsp;Jianxi Zhang ,&nbsp;Zhenghong Sun ,&nbsp;Yongkang Diao ,&nbsp;Kongying Lin ,&nbsp;Yongyi Zeng","doi":"10.1016/j.iliver.2024.100109","DOIUrl":"10.1016/j.iliver.2024.100109","url":null,"abstract":"<div><h3>Background</h3><p>Tyrosine kinase inhibitors (TKIs) and anti-PD-1 antibodies in combination provide survival benefits for patients with unresectable hepatocellular carcinoma (uHCC). However, the tool used to determine which patients likely benefit most from this treatment strategy has not been reported. We sought to develop a prognostic scoring system based on tumor burden score (TBS) and alpha-fetoprotein (AFP) to predict the long-term prognosis of uHCC treated with TKIs and anti-PD-1 antibodies.</p></div><div><h3>Methods</h3><p>Data on patients with uHCC treated with TKIs and anti-PD-1 antibodies from multiple centers were collected. The prognostic accuracy of TBS, AFP, Barcelona Clinic Liver Cancer (BCLC), and CTA (Combined TBS and AFP) for 2-year progression-free survival (PFS) and overall survival (OS) was evaluated.</p></div><div><h3>Results</h3><p>Overall, 278 patients with uHCC treated with TKIs and anti-PD-1 antibodies were enrolled, including 48 BCLC-B and 230 BCLC-C HCC patients. CTA (AUC = 0.721 and 0.683) outperformed TBS (AUC = 0.680 and 0.621), AFP (AUC = 0.606 and 0.594), and BCLC staging (AUC = 0.551 and 0.555) in predicting PFS and OS. The 2-year PFS and OS for low CTA (low TBS/low AFP) were 65.7% and 94.4%, respectively, which were significantly higher than 21.6% and 44.9% (<em>p</em> &lt; 0.001 and <em>p</em> = 0.002), respectively, for intermediate CTA (low TBS/high AFP or high TBS/low AFP) and 8.7% and 12.1% (both <em>p</em> &lt; 0.001), respectively, for high CTA (high TBS/high AFP). Multivariable Cox regression analysis indicated that CTA grading was an independent prognostic factor for PFS and OS (referent: low CTA; intermediate CTA, HR 2.87 and 7.17; high CTA, HR 5.52 and 10.31, respectively).</p></div><div><h3>Conclusions</h3><p>CTA grading is an accurate tool for stratifying the prognosis of uHCC treated with TKIs and anti-PD-1 antibodies and may help determine which patients may benefit more from this treatment strategy.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100109"},"PeriodicalIF":0.0,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000343/pdfft?md5=6af753a448301ae70ed3eddae4d63605&pid=1-s2.0-S2772947824000343-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142040260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum IP-10 increase correlated with PEG-IFNα response in nucleot(s)ide analogs-treated patients with chronic hepatitis B","authors":"Wen-Xin Wang ,&nbsp;Xiaoyan Li ,&nbsp;Xue-Yuan Jin ,&nbsp;Rui Jia ,&nbsp;Hong-Min Wang ,&nbsp;Shuang-Nan Zhou ,&nbsp;Xin Zhang ,&nbsp;Ying-Ying Gao ,&nbsp;Fu-Sheng Wang ,&nbsp;Junliang Fu","doi":"10.1016/j.iliver.2024.100107","DOIUrl":"10.1016/j.iliver.2024.100107","url":null,"abstract":"<div><h3>Background and aims</h3><p>To investigate the association between serum IP-10 and HBsAg levels in chronic hepatitis B (CHB) patients previously treated with nucleot(s)ide analogs (NAs) followed by combined treatment with an NA and pegylated interferon alpha (PEG-IFNα).</p></div><div><h3>Methods</h3><p>Ninety-nine patients with serum levels of HBsAg &lt;3000 IU/mL and HBV DNA &lt;20 IU/mL who received prior NA treatment were enrolled. Participants were administered either NA monotherapy (NA group) or combination therapy with PEG-IFNα (Add-on group). Laboratory indicators and IP-10 levels were assessed in serial peripheral blood samples collected at 12- and 24-week intervals. The outcome of this study was a loss or &gt;1 log₁₀ IU/mL decline in serum HBsAg.</p></div><div><h3>Results</h3><p>After 48 weeks of antiviral therapy, none of the 27 NA group patients and 15 of the 72 Add-on group patients achieved HBsAg loss. Baseline serum HBsAg and IP-10 levels were equivalent across both groups. The combination treatment led to a decrease in serum HBsAg levels and an early increase in IP-10 levels. Furthermore, a moderate increase in IP-10 levels at weeks 12 or 24 was correlated with loss and decline of HBsAg in the Add-on group. Receiver operating characteristic curve and regression analyses demonstrated that a moderate increase in serum IP-10 levels at weeks 12 or 24 was predictive of HBsAg loss and decline in the Add-on group (<em>p</em> &lt; 0.05).</p></div><div><h3>Conclusion</h3><p>An early and moderate increase in the serum IP-10 level was correlated with responses to PEG-IFNα among patients with CHB treated with NAs.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100107"},"PeriodicalIF":0.0,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277294782400032X/pdfft?md5=05062282b65b7d860c2f3674209bd868&pid=1-s2.0-S277294782400032X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142012970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-term effects of modified ultrasonography in laparoscopic anatomical hepatectomy for hepatocellular carcinoma","authors":"Xun Wang ,&nbsp;Xuan Meng ,&nbsp;Liming Wang,&nbsp;Peng Wang,&nbsp;Zhihao Wang,&nbsp;Weiqi Rong,&nbsp;Zhiyu Lu,&nbsp;Hongguang Wang","doi":"10.1016/j.iliver.2024.100106","DOIUrl":"10.1016/j.iliver.2024.100106","url":null,"abstract":"<div><h3>Background and aims</h3><p>Laparoscopic hepatectomy is challenging, and ultrasound guidance is an effective aid but lacks standardization. This study aimed to evaluate a modified approach for laparoscopic ultrasonography to enhance surgical outcomes.</p></div><div><h3>Methods</h3><p>Between January 2020 and August 2023, 122 patients who underwent real-time ultrasound-guided laparoscopic anatomical hepatectomy for hepatocellular carcinoma were enrolled and divided into modified and traditional ultrasonography groups. The modified ultrasound application comprised intraoperative protocol-based laparoscopic ultrasonography comprising application scenarios; standardized positions for the surgeon, trocar, and probe; and the resulting standardized sections for various laparoscopic liver resections. Clinical characteristics and perioperative outcomes were compared between the two groups. Subgroup analysis was performed and comprised techniques for modified duct structure identification and portal vein branch puncture; both techniques were used in fluorescence probe-mounted laparoscopic liver resection using negative and positive staining procedures, respectively.</p></div><div><h3>Results</h3><p>The traditional and modified groups comprised 64 and 58 patients, respectively. The patients’ background characteristics were not significantly different between the groups. Surgical duration (283.4 min vs. 225.1 min; <em>p</em> &lt; 0.001), Pringle maneuver duration (47.4 min vs. 39.5 min; <em>p</em> = 0.014), bleeding volume (258.6 mL vs. 174.8 mL; <em>p</em> = 0.005), overall complication rate (31.3% vs. 15.5%; <em>p</em> = 0.041), and postoperative stay were significantly greater in the traditional vs. modified ultrasonography groups, respectively. The modified method positively affected the number of punctures, success rate of staining, intraoperative bleeding volume, and operation duration.</p></div><div><h3>Conclusions</h3><p>Modified ultrasonography improves the safety and effectiveness of laparoscopic hepatectomy. Ultrasonography is pivotal, especially in fluorescence probe-assisted laparoscopic liver resection.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100106"},"PeriodicalIF":0.0,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000318/pdfft?md5=be0303c5aa9e5b1f82a1533c9b8ebe58&pid=1-s2.0-S2772947824000318-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141708607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CCL16 inhibits tumor proliferation and metastasis in HCC by impacting CK19 phenotype","authors":"Huigang Li ,&nbsp;Jianyong Zhuo ,&nbsp;Peiru Zhang ,&nbsp;Jinyan Chen ,&nbsp;Zuyuan Lin ,&nbsp;Xudong Yang ,&nbsp;Ruijie Zhao ,&nbsp;Chenghao Cao ,&nbsp;Wei Shen ,&nbsp;Chiyu He ,&nbsp;Hao Chen ,&nbsp;Ting Lv ,&nbsp;Xuyong Wei ,&nbsp;Shusen Zheng ,&nbsp;Xiao Xu ,&nbsp;Di Lu","doi":"10.1016/j.iliver.2024.100096","DOIUrl":"10.1016/j.iliver.2024.100096","url":null,"abstract":"<div><h3>Background and aims</h3><p>Cytokeratin 19–positive (CK19+) hepatocellular carcinoma (HCC) is an aggressive subtype with poor outcomes. The initiation and development of CK19+ HCC in the background of liver cirrhosis remains unclear. This study investigated the role of the cirrhosis-related gene C–C motif chemokine ligand 16 (CCL16) in the development of CK19+ HCC.</p></div><div><h3>Methods</h3><p>Datasets from Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) were analyzed to screen and validate the genes associated with CK19+ HCC. A total of 102 HCC patients were included for tissue microarray analysis. Gain-of-function experiments were conducted to investigate the biological functions of CCL16. CIBERSORT was used to investigate the correlation of CCL16 and immune infiltration.</p></div><div><h3>Results</h3><p>GEO dataset analysis showed that CK19+ HCC had lower expression of CCL16. In both TCGA dataset and our HCC cohort, CCL16 expression was negatively correlated with CK19 expression (<em>P</em> ​&lt; ​0.05) and its expression was higher in para-tumor than tumor tissues (<em>P</em> ​&lt; ​0.001). Moreover, low CCL16 expression was related to advanced stage and poor overall survival (<em>P</em> ​&lt; ​0.05). CCL16 overexpression downregulated CK19 expression and impacted the sphere formation ability of HCC cells. Overexpression of CCL16 inhibited the cell proliferation, migration, and invasion of HCC cell lines. Immune analysis showed HCC with high CCL16 expression had more infiltration of mast cells. HCC patients with both low CCL16 expression and low mast cells had the worst prognosis (<em>P</em> ​&lt; ​0.001).</p></div><div><h3>Conclusion</h3><p>Our data indicated that CCL16 downregulated the expression of CK19 and inhibited the malignant phenotype of HCC.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 2","pages":"Article 100096"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000215/pdfft?md5=b5bdf50abc10a7dd4931f45f1e281ee8&pid=1-s2.0-S2772947824000215-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141133699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic syndrome is associated with significant hepatic fibrosis and steatosis in patients with nonalcoholic steatohepatitis","authors":"Qian-Qian Li ,&nbsp;Yu-Ting Xiong ,&nbsp;Danni Wang ,&nbsp;Ke-Xin Wang ,&nbsp;Chang Guo ,&nbsp;Yi-Ming Fu ,&nbsp;Xiao-Xia Niu ,&nbsp;Chun-Yan Wang ,&nbsp;Jian-Jun Wang ,&nbsp;Dong Ji ,&nbsp;Zhi-Fang Bai","doi":"10.1016/j.iliver.2024.100094","DOIUrl":"10.1016/j.iliver.2024.100094","url":null,"abstract":"<div><h3>Background and aims</h3><p>Nonalcoholic steatohepatitis (NASH), an inflammatory form of non-alcoholic fatty liver disease, can progress to advanced liver fibrosis, cirrhosis, and liver cancer. Metabolic syndrome (MetS) parallels the prevalence of non-alcoholic fatty liver disease/NASH and increases patients’ risk of advanced liver disease. This study aimed to determine whether MetS was associated with the histological progression of NASH.</p></div><div><h3>Methods</h3><p>Patients with liver biopsy-proven NASH were retrospectively screened and categorized into two groups for each histological feature: with (&lt;2 points) or without (≥2 points) significant hepatic steatosis/inflammation/fibrosis. Multivariable logistic regression was used to explore the association between MetS and histological features.</p></div><div><h3>Results</h3><p>In total, 386 patients with a median age of 33.0 years were enrolled; among them, 35.2% were female, and 41.2% had MetS. The proportion of significant hepatic fibrosis and steatosis in those with MetS was significantly higher than in those without MetS (<em>p</em> &lt; 0.05). Multivariable logistic regression analyses showed that MetS remained significantly associated with significant hepatic fibrosis (adjusted odds ratio: 1.852, 95% confidence interval: 1.042–3.292, <em>p</em> = 0.036), and severe hepatic steatosis (adjusted odds ratio: 2.008, 95% confidence interval: 1.030–3.914, <em>p</em> = 0.041).</p></div><div><h3>Conclusion</h3><p>MetS was associated with significant hepatic fibrosis and steatosis in patients with NASH. Our results suggest that NASH patients with MetS should be closely monitored and given targeted intervention and treatment, which may help to prevent disease progression and mitigate the growing burden of NASH.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 2","pages":"Article 100094"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000197/pdfft?md5=ea4ea081a890891e2b017963d6e2344a&pid=1-s2.0-S2772947824000197-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140768689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors related to significant hepatic inflammation in patients with acute drug-induced liver injury","authors":"Yu-Ting Xiong ,&nbsp;Jian-Fei Wang ,&nbsp;Le Li ,&nbsp;Zhi-Fang Bai ,&nbsp;Yan Liu ,&nbsp;Ang Huang ,&nbsp;Ke-Xin Wang ,&nbsp;Yiming Fu ,&nbsp;Wucai Yang ,&nbsp;Chang Guo ,&nbsp;Mengwen He ,&nbsp;Wen-Chang Wang ,&nbsp;Chun-Yan Wang ,&nbsp;Dong Ji","doi":"10.1016/j.iliver.2024.100095","DOIUrl":"10.1016/j.iliver.2024.100095","url":null,"abstract":"<div><h3>Background</h3><p>Currently, research on biopsy-proven acute drug-induced liver injury (DILI) remains limited. This study aimed to identify clinical characteristics and risk factors for significant hepatic inflammation in patients with acute DILI.</p></div><div><h3>Methods</h3><p>An ambispective cohort study was conducted on biopsy-proven acute DILI patients admitted to our hospital from 2012 to 2018. Using the Scheuer scoring system, patients were categorized into G0-2 or G3-4 groups and followed up for 12 months after first admission. Clinical characteristics and outcomes were retrieved from medical records.</p></div><div><h3>Results</h3><p>The median age of the 157 enrolled patients (65.6% female) was 40.4 (interquartile range (IQR), 31.9–49.1) years. The median latency and length of hospitalization were 30.0 (IQR, 5.0–60.0) and 18.0 (IQR, 12.0–26.0) days. The proportions of patients in the G0-2 and G3-4 groups were 54.8% and 45.2%, respectively. Logistic regression analysis revealed that females (odds ratio (OR): 2.623, 95% confidence interval (CI): 1.169–5.887, <em>p</em> = 0.019), higher body mass index (OR: 1.168, 95% CI: 1.029–1.325, <em>p</em> = 0.016), higher total bilirubin (OR: 1.004, 95% CI: 1.000–1.007, <em>p</em> = 0.047), and lower prothrombin activity (OR: 0.976, 95% CI: 0,957–0.995, <em>p</em> = 0.013) were associated with significant hepatic inflammation. The predominance of the hepatocellular injury pattern (60.5%) at admission transformed into a predominance of the cholestatic pattern (60.5%) at discharge. During follow-up, 23 patients (14.6%) developed chronic DILI, with nine patients (5.7%) progressing to cirrhosis. Moreover, 15 female patients (9.6%) developed autoimmunity (3cases in the G0-2 group vs 12 cases in the G3-4 group, <em>p</em> &lt; 0.05).</p></div><div><h3>Conclusions</h3><p>Acute DILI patients with high-risk factors were more likely to develop significant hepatic inflammation, and females with significant inflammation were at a higher risk of developing autoimmunity during follow-up.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 2","pages":"Article 100095"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000203/pdfft?md5=645003e67eda5eb4ceb14fc881bc62ed&pid=1-s2.0-S2772947824000203-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141038690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance comparisons of two commonly used multi-biomarker-based scores for detection of hepatocellular carcinoma in non-alcoholic fatty liver disease","authors":"Wei Ouyang ,&nbsp;Ming-Da Wang ,&nbsp;Ming-Cheng Guan ,&nbsp;Yong-Kang Diao ,&nbsp;Li-Yang Sun ,&nbsp;Nan-Ya Wang ,&nbsp;Feng Shen ,&nbsp;Hong Zhu ,&nbsp;Tian Yang","doi":"10.1016/j.iliver.2024.100098","DOIUrl":"10.1016/j.iliver.2024.100098","url":null,"abstract":"<div><h3>Background and aims</h3><p>The ASAP and GALAD scores are widely used diagnostic models for detecting hepatocellular carcinoma (HCC), incorporating factors such as sex, age, alpha-fetoprotein (AFP), protein induced by vitamin K absence or antagonist-II (PIVKA-II), and lens culinaris agglutinin-reactive fraction of AFP (AFP-L3%). This study compares the diagnostic efficacy of the ASAP and GALAD scores in the early detection of HCC in patients with non-alcoholic fatty liver disease (NAFLD).</p></div><div><h3>Methods</h3><p>NAFLD patients with and without HCC were recruited from 12 Chinese tertiary hospitals. Serum levels of AFP, PIVKA-II, and AFP-L3% were measured. The diagnostic accuracy of individual biomarkers, the ASAP score, and the GALAD score in detecting NAFLD-HCC at various stages was evaluated using receiver operating characteristic (ROC) curves and area under the curve (AUC) values.</p></div><div><h3>Results</h3><p>In a cohort of 147 NAFLD-HCC cases and 460 NAFLD controls, both the ASAP and GALAD scores outperformed individual biomarkers in detecting NAFLD-HCC. The ASAP score demonstrated a high AUC of 0.910 (sensitivity: 80.3%, specificity: 92.8%) for identifying NAFLD-HCC at all stages, surpassing AFP (AUC: 0.716, <em>P</em> &lt; 0.001), PIVKA-II (AUC: 0.849, <em>P</em> &lt; 0.001), AFP-L3% (AUC: 0.663, <em>P</em> &lt; 0.001), and the GALAD score (AUC: 0.882, <em>P</em> = 0.014). Comparable results were observed for early-stage NAFLD-HCC and for detecting HCC in NAFLD patients with or without cirrhosis.</p></div><div><h3>Conclusion</h3><p>The ASAP score, which excludes the AFP-L3% indicator, demonstrated superior performance in differentiating NAFLD-HCC compared to the GALAD score, suggesting its potential for early screening of HCC in NAFLD patients.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 2","pages":"Article 100098"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000239/pdfft?md5=3f1832536c1a71cc8de9d107a8cce2c7&pid=1-s2.0-S2772947824000239-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141139101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver transplantation and immune tolerance: Setting the stage for optimal post-transplant status","authors":"Jiaying Cao,&nbsp;Qi Ling","doi":"10.1016/j.iliver.2024.100097","DOIUrl":"10.1016/j.iliver.2024.100097","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 2","pages":"Article 100097"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000227/pdfft?md5=88237d48481d600184c150e90112c29a&pid=1-s2.0-S2772947824000227-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141138982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}